Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.50 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.45 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.36 |
| ▸ | TERT | O14746 | 3/20 | 0.35 |
| ▸ | BLM | P54132 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10534314 | 1.00 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2PPARGMAPT | |
| SCHEMBL28645015 | 1.00 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2PPARGMAPT | |
| SCHEMBL17334530 | 0.88 | PPARG (0.48) | HCAR2KEAP1NFE2L2PPARGMAPT | |
| SCHEMBL28549553 | 0.84 | PPARG (0.57) | PPARGMAPTALDH1A1CYP19A1OXER1 | |
| SCHEMBL3017777 | 0.84 | PPARG (0.57) | PPARGMAPTALDH1A1CYP19A1OXER1 | |
| SCHEMBL11745554 | 0.84 | PPARG (0.57) | PPARGMAPTALDH1A1CYP19A1OXER1 | |
| SCHEMBL810920 | 0.83 | AKT1 (0.54) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL28152408 | 0.83 | AKT1 (0.54) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL810921 | 0.83 | AKT1 (0.54) | HCAR2KEAP1NFE2L2MAPTALDH1A1 | |
| SCHEMBL21802620 | 0.82 | PPARG (0.43) | PPARGMAPTALDH1A1CYP19A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3002285-B1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO (JP) | 2018-08-29 | — | — | EP | disclosed |
| US-9974777-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9974777-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-05-22 | — | — | US | disclosed |
| US-9862721-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2018-01-09 | — | — | US | disclosed |
| US-20170320819-A1 | METHOD FOR PRODUCING EPSILON-CAPROLACTAM | TORAY INDUSTRIES, INC. (JP) | 2017-11-09 | — | — | US | disclosed |
| US-20170320819-A1 | METHOD FOR PRODUCING EPSILON-CAPROLACTAM | TORAY INDUSTRIES, INC. (JP) | 2017-11-09 | — | — | US | disclosed |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-9636330-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-02 | — | — | US | disclosed |
| US-9636330-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-05-02 | — | — | US | disclosed |
| US-9006246-B2 | Tetrahydrocarboline derivative | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| EP-2687531-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| EP-2687531-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2014-01-22 | — | — | EP | disclosed |
| US-20130345426-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-12-26 | — | — | US | disclosed |
| EP-2592081-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2013-05-15 | — | — | EP | disclosed |
| EP-2592081-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO Pharmaceutical Co., Ltd. (JP) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-05-02 | — | — | US | disclosed |
| WO-2012127885-A1 | TETRAHYDROCARBOLINE DERIVATIVE | 小野薬品工業株式会社 (JP) | 2012-09-27 | — | — | WO | disclosed |
| WO-2012005227-A1 | TETRAHYDROCARBOLINE DERIVATIVE | 小野薬品工業株式会社 (JP) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320819-A1 | METHOD FOR PRODUCING EPSILON-CAPROLACTAM | HACL2, HM13, ALAD | HCAR2 193/4885KEAP1 3942/4885NFE2L2 4062/4885 |
| US-20130345426-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | HCAR2 383/4885KEAP1 2087/4885NFE2L2 2934/4885 |
| US-20170189386-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | HCAR2 397/4885KEAP1 2033/4885NFE2L2 2887/4885 |
| US-20130109699-A1 | TETRAHYDROCARBOLINE DERIVATIVE | ENPP2, ENPP1, ACER2 | HCAR2 383/4885KEAP1 2087/4885NFE2L2 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.